CD18 Blocking Peptide
Référence MBS8237822-1mg
Conditionnement : 1mg
Marque : MyBiosource
Contactez votre distributeur local :
Téléphone : +1 850 650 7790
CD18 Blocking Peptide – >85% Purity
For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS8237822MBS8237822 is a blocking peptide targeting ITGB2. Also known as CD18 Blocking Peptide. Reactive in Human, Monkey. Host: Synthetic. The peptide is used to block Anti-CD18 Antibody (MBS8227490) reactivity. More details
Product Overview
Online Datasheet in PDFProduct Name
CD18 (ITGB2), Blocking Peptide
Full Product Name
CD18 Blocking Peptide
Product Gene Name
ITGB2 blocking peptide
Product Synonym Names
CD18; MFI7; Integrin beta-2; Cell surface adhesion glycoproteins LFA-1/CR3/p150,95 subunit beta; Complement receptor C3 subunit beta; CD18
Host
Synthetic
Species Reactivity
Human, Monkey
Form/Format
Lyophilized powder
Purity/Purification
>85%
Preparation and Storage
Store at -20°C for one year.
Antibody/Peptide Pairs
CD18 peptide (MBS8237822) is used for blocking the activity of CD18 antibody (MBS8227490)
OMIM
116920
Quality Control
The quality of the peptide was evaluated by reversed-phase HPLC and by mass spectrometry.
Directions for Use
Blocking Peptide to the diluted primary antibody in a molar ratio of 10:1 (peptide to antibody) and incubate the mixture at 4°C for overnight or at room temperature for 2 hours.
Applications Tested/Suitable for ITGB2 blocking peptide
Blocking (BL)
Other Notes
Small volumes of ITGB2 blocking peptide vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Additional Details
NCBI/Uniprot data below describe general gene information for ITGB2. It may not necessarily be applicable to this product.
NCBI Official Full Name
integrin beta-2 isoform 1
NCBI Official Synonym Full Names
integrin, beta 2 (complement component 3 receptor 3 and 4 subunit)
NCBI Official Symbol
ITGB2
NCBI Official Synonym Symbols
LAD; CD18; MF17; MFI7; LCAMB; LFA-1; MAC-1
UniProt Protein Name
Integrin beta-2
UniProt Synonym Protein Names
Cell surface adhesion glycoproteins LFA-1/CR3/p150,95 subunit beta; Complement receptor C3 subunit beta; CD_antigen: CD18
Protein Family
Integrin
UniProt Gene Name
ITGB2
UniProt Synonym Gene Names
CD18; MFI7
UniProt Entry Name
ITB2_HUMAN
NCBI Protein Information
integrin beta-2
NCBI Summary for ITGB2
This gene encodes an integrin beta chain, which combines with multiple different alpha chains to form different integrin heterodimers. Integrins are integral cell-surface proteins that participate in cell adhesion as well as cell-surface mediated signalling. The encoded protein plays an important role in immune response and defects in this gene cause leukocyte adhesion deficiency. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2014]
Show more UniProt Comments for ITGB2
ITGB2: the integrin beta 2 subunit. Can combine with multiple partners resulting in different integrins. For example, beta 2 combines with the alpha L chain to form the integrin LFA-1, and combines with the alpha M chain to form the integrin Mac-1. Participates in cell adhesion as well as cell-surface mediated signaling. Defects are the cause of leukocyte adhesion deficiency type I (LAD1).
Protein type: Motility/polarity/chemotaxis; Cell adhesion; Cell surface; Receptor, misc.; Membrane protein, integral
Chromosomal Location of Human Ortholog: 21q22.3
Cellular Component: cell surface; membrane; plasma membrane; integrin complex; receptor complex; vesicle; lipid raft
Molecular Function: protein binding; protein heterodimerization activity; metal ion binding; protein complex binding; ICAM-3 receptor activity; cell adhesion molecule binding; glycoprotein binding; protein kinase binding
Biological Process: extracellular matrix organization and biogenesis; positive regulation of nitric oxide biosynthetic process; apoptosis; cell-matrix adhesion; natural killer cell activation; receptor clustering; activation of NF-kappaB transcription factor; regulation of cell shape; leukocyte adhesion; cell-cell signaling; cellular extravasation; cell adhesion; inflammatory response; regulation of peptidyl-tyrosine phosphorylation; toll-like receptor 4 signaling pathway; aging; integrin-mediated signaling pathway; neutrophil chemotaxis; regulation of immune response; activated T cell proliferation; leukocyte migration during inflammatory response; heterotypic cell-cell adhesion; positive regulation of angiogenesis; toll-like receptor signaling pathway; endothelial cell migration; innate immune response; blood coagulation; leukocyte migration
Disease: Leukocyte Adhesion Deficiency, Type I
Show more Protein type: Motility/polarity/chemotaxis; Cell adhesion; Cell surface; Receptor, misc.; Membrane protein, integral
Chromosomal Location of Human Ortholog: 21q22.3
Cellular Component: cell surface; membrane; plasma membrane; integrin complex; receptor complex; vesicle; lipid raft
Molecular Function: protein binding; protein heterodimerization activity; metal ion binding; protein complex binding; ICAM-3 receptor activity; cell adhesion molecule binding; glycoprotein binding; protein kinase binding
Biological Process: extracellular matrix organization and biogenesis; positive regulation of nitric oxide biosynthetic process; apoptosis; cell-matrix adhesion; natural killer cell activation; receptor clustering; activation of NF-kappaB transcription factor; regulation of cell shape; leukocyte adhesion; cell-cell signaling; cellular extravasation; cell adhesion; inflammatory response; regulation of peptidyl-tyrosine phosphorylation; toll-like receptor 4 signaling pathway; aging; integrin-mediated signaling pathway; neutrophil chemotaxis; regulation of immune response; activated T cell proliferation; leukocyte migration during inflammatory response; heterotypic cell-cell adhesion; positive regulation of angiogenesis; toll-like receptor signaling pathway; endothelial cell migration; innate immune response; blood coagulation; leukocyte migration
Disease: Leukocyte Adhesion Deficiency, Type I
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Product Note
Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.
Product PubMed Publications
Products associated with ITGB2 blocking peptide
| Reference Product | PubMed Publications |
|---|---|
| ITGAM blocking peptide | >1656 publications with ITGB2 and ITGAM |
| ITGAL blocking peptide | >1097 publications with ITGB2 and ITGAL |
| ICAM1 blocking peptide | >886 publications with ITGB2 and ICAM1 |
| ITGAX blocking peptide | >411 publications with ITGB2 and ITGAX |
| ICAM2 blocking peptide | >59 publications with ITGB2 and ICAM2 |
| ICAM3 blocking peptide | >48 publications with ITGB2 and ICAM3 |
| ITGAD blocking peptide | >19 publications with ITGB2 and ITGAD |
| ITGA5 blocking peptide | >1 publications with ITGB2 and ITGA5 |
Pathways associated with ITGB2 blocking peptide
| Products by Pathway | Pathway Diagram |
|---|---|
| Adaptive Immune System Pathway antibodies | Adaptive Immune System Pathway Diagram |
| Amoebiasis Pathway antibodies | Amoebiasis Pathway Diagram |
| Amoebiasis Pathway antibodies | Amoebiasis Pathway Diagram |
| CXCR3-mediated Signaling Events Pathway antibodies | CXCR3-mediated Signaling Events Pathway Diagram |
| Cell Adhesion Molecules (CAMs) Pathway antibodies | Cell Adhesion Molecules (CAMs) Pathway Diagram |
| Cell Adhesion Molecules (CAMs) Pathway antibodies | Cell Adhesion Molecules (CAMs) Pathway Diagram |
| Cell Surface Interactions At The Vascular Wall Pathway antibodies | Cell Surface Interactions At The Vascular Wall Pathway Diagram |
| Extracellular Matrix Organization Pathway antibodies | Extracellular Matrix Organization Pathway Diagram |
| Focal Adhesion Pathway antibodies | Focal Adhesion Pathway Diagram |
| HIF-1-alpha Transcription Factor Network Pathway antibodies | HIF-1-alpha Transcription Factor Network Pathway Diagram |
Diseases associated with ITGB2 blocking peptide
| Disease Name | Pubmed Publications |
|---|---|
| Inflammation Antibodies | >936 publications with ITGB2 and Inflammation |
| Necrosis Antibodies | >622 publications with ITGB2 and Necrosis |
| Cardiovascular Diseases Antibodies | >409 publications with ITGB2 and Cardiovascular Diseases |
| Disease Models, Animal Antibodies | >239 publications with ITGB2 and Disease Models, Animal |
| Lung Diseases Antibodies | >221 publications with ITGB2 and Lung Diseases |
| Leukocyte-Adhesion Deficiency Syndrome Antibodies | >168 publications with ITGB2 and Leukocyte-Adhesion Deficiency Syndrome |
| Heart Diseases Antibodies | >130 publications with ITGB2 and Heart Diseases |
| Leukocyte Disorders Antibodies | >119 publications with ITGB2 and Leukocyte Disorders |
| Hypersensitivity Antibodies | >115 publications with ITGB2 and Hypersensitivity |
| Atherosclerosis Antibodies | >76 publications with ITGB2 and Atherosclerosis |
Organs/Tissues associated with ITGB2 blocking peptide
| Organ/Tissue Name | Pubmed Publications |
|---|---|
| Blood Antibodies | >3760 publications with ITGB2 and Blood |
| Lung Antibodies | >377 publications with ITGB2 and Lung |
| Bone Antibodies | >295 publications with ITGB2 and Bone |
| Bone Marrow Antibodies | >265 publications with ITGB2 and Bone Marrow |
| Heart Antibodies | >188 publications with ITGB2 and Heart |
| Muscle Antibodies | >166 publications with ITGB2 and Muscle |
| Liver Antibodies | >128 publications with ITGB2 and Liver |
| Embryonic Tissue Antibodies | >124 publications with ITGB2 and Embryonic Tissue |
| Brain Antibodies | >105 publications with ITGB2 and Brain |
| Spleen Antibodies | >104 publications with ITGB2 and Spleen |
Vous serez peut-être également intéressé par les produits suivants :
Référence
Description
Cond.
Prix HT